Society Targets MRSA With New Guidelines

The Infectious Diseases Society of America rolled out its first-ever guidelines for treating methicillin-resistant Staphylococcus aureus – including recommendations to battle the growing threat posed by MRSA-related skin and soft-tissue infections.

The comprehensive guidelines also outline evidence-based approaches on topics ranging from personal hygiene and wound care to antibiotic therapies for invasive MRSA, as well as options after vancomycin treatment failure.

The guidelines' primary objective is "to provide recommendations on the management of some of the most common clinical syndromes encountered by adult and pediatric clinicians who care for patients with MRSA infections," according to the executive summary, published online Jan. 5 (Clin. Infect. Dis. 2010 [doi:10.1093/cid/ciq146]).

The guidelines provide adult and pediatric clinicians with guidance on how to treat relatively uncomplicated MRSA infections, as well as more serious infections, according to Dr. Catherine Liu, the guidelines' lead author and assistant clinical professor in the division of infectious diseases, University of California, San Francisco. The recommendations cover community- and hospital-associated MRSA infections, she added.

MRSA infections account for about 60% of skin infections seen in U.S. emergency departments, and invasive MRSA infections cause about 18,000 deaths a year, according to the Infectious Diseases Society of America (IDSA).

The evidence-based guidelines, which will be published in the Feb. 1 issue of Clinical Infectious Diseases, have been endorsed by the Pediatric Infectious Diseases Society, the American College of Emergency Physicians, and the American Academy of Pediatrics.

The guidelines are voluntary and "are not intended to take the place of a doctor's judgment, but rather support the decision-making process, which must be individualized according to each patient's circumstances," according to a statement issued by IDSA, which funded the guidelines.

A 13-member expert panel reviewed hundreds of scientific studies, papers, and presentations to create the recommendations. The guidelines' sections start with a clinical question, followed by a numbered list of recommendations and a summary of the most relevant evidence to support the recommendations. In most cases, the sections include information on pediatric considerations. The guidelines also highlight areas that are controversial because of limited or conflicting data.

The first topic addressed is the management of skin and soft tissue infections due to MRSA, which have become a significant problem in the past few years, Dr. Liu said in an interview. For example, MRSA is now the predominant organism causing skin infections in patients who present to emergency departments with skin infections, she noted.

The guidelines cover multiple types of skin infections, including abscesses, cellulitis, and more complicated skin infections. The guidelines also offer recommendations on the role of antibiotics, including whether or not they need to be used, situations in which they may not be indicated, and when they definitely should be used. They also offer guidance " on specific types of antibiotic choices that clinicians should consider," Dr. Liu noted.

Other topics covered include the management of MRSA pneumonia, bacteremia, and infective endocarditis; central nervous system infections; and bone and joint infections. Additional sections review the role of adjunctive therapies in the treatment of MRSA infections, MRSA infections in neonates, and specific recommendations on vancomycin dosing and monitoring.

IDSA will update the guidelines as more information and newer antibiotics become available. However, timely updating can be difficult because of the review and publication process, Dr. Liu noted.

For example, the Food and Drug Administration approved the intravenous cephalosporin antibiotic ceftaroline in October 2010 for acute bacterial skin and soft tissue infections, including cases caused by MRSA. But approval came after the IDSA guidelines were finalized, and that information was not included. Nonetheless, the guidelines note that ceftaroline "may become available in the near future for the treatment" of complicated skin and skin structure infections, Dr. Liu said.

The guidelines do not address active surveillance testing or other strategies aimed at preventing MRSA in health care settings, topics that have been addressed in previously released guidelines.

IDSA funded the development of the guidelines. Of the expert panel's 13 members, 9 reported having potential conflicts of interest that included honoraria or research support from, or having served as a consultant or adviser to, pharmaceutical companies, including Astellas, Cubist Pharmaceutical, Forest, Merck, Ortho-McNeil, Pfizer, Sanofi-Aventis, Schering-Plough, and Theravance. The remaining authors of the guidelines, including the lead author, Dr. Catherine Liu, reported no conflicts.

The Infectious Diseases Society of America rolled out its first-ever guidelines for treating methicillin-resistant Staphylococcus aureus – including recommendations to battle the growing threat posed by MRSA-related skin and soft-tissue infections.

The comprehensive guidelines also outline evidence-based approaches on topics ranging from personal hygiene and wound care to antibiotic therapies for invasive MRSA, as well as options after vancomycin treatment failure.

The guidelines' primary objective is "to provide recommendations on the management of some of the most common clinical syndromes encountered by adult and pediatric clinicians who care for patients with MRSA infections," according to the executive summary, published online Jan. 5 (Clin. Infect. Dis. 2010 [doi:10.1093/cid/ciq146]).

The guidelines provide adult and pediatric clinicians with guidance on how to treat relatively uncomplicated MRSA infections, as well as more serious infections, according to Dr. Catherine Liu, the guidelines' lead author and assistant clinical professor in the division of infectious diseases, University of California, San Francisco. The recommendations cover community- and hospital-associated MRSA infections, she added.

MRSA infections account for about 60% of skin infections seen in U.S. emergency departments, and invasive MRSA infections cause about 18,000 deaths a year, according to the Infectious Diseases Society of America (IDSA).

The evidence-based guidelines, which will be published in the Feb. 1 issue of Clinical Infectious Diseases, have been endorsed by the Pediatric Infectious Diseases Society, the American College of Emergency Physicians, and the American Academy of Pediatrics.

The guidelines are voluntary and "are not intended to take the place of a doctor's judgment, but rather support the decision-making process, which must be individualized according to each patient's circumstances," according to a statement issued by IDSA, which funded the guidelines.

A 13-member expert panel reviewed hundreds of scientific studies, papers, and presentations to create the recommendations. The guidelines' sections start with a clinical question, followed by a numbered list of recommendations and a summary of the most relevant evidence to support the recommendations. In most cases, the sections include information on pediatric considerations. The guidelines also highlight areas that are controversial because of limited or conflicting data.

The first topic addressed is the management of skin and soft tissue infections due to MRSA, which have become a significant problem in the past few years, Dr. Liu said in an interview. For example, MRSA is now the predominant organism causing skin infections in patients who present to emergency departments with skin infections, she noted.

The guidelines cover multiple types of skin infections, including abscesses, cellulitis, and more complicated skin infections. The guidelines also offer recommendations on the role of antibiotics, including whether or not they need to be used, situations in which they may not be indicated, and when they definitely should be used. They also offer guidance " on specific types of antibiotic choices that clinicians should consider," Dr. Liu noted.

Other topics covered include the management of MRSA pneumonia, bacteremia, and infective endocarditis; central nervous system infections; and bone and joint infections. Additional sections review the role of adjunctive therapies in the treatment of MRSA infections, MRSA infections in neonates, and specific recommendations on vancomycin dosing and monitoring.

IDSA will update the guidelines as more information and newer antibiotics become available. However, timely updating can be difficult because of the review and publication process, Dr. Liu noted.

For example, the Food and Drug Administration approved the intravenous cephalosporin antibiotic ceftaroline in October 2010 for acute bacterial skin and soft tissue infections, including cases caused by MRSA. But approval came after the IDSA guidelines were finalized, and that information was not included. Nonetheless, the guidelines note that ceftaroline "may become available in the near future for the treatment" of complicated skin and skin structure infections, Dr. Liu said.

The guidelines do not address active surveillance testing or other strategies aimed at preventing MRSA in health care settings, topics that have been addressed in previously released guidelines.

IDSA funded the development of the guidelines. Of the expert panel's 13 members, 9 reported having potential conflicts of interest that included honoraria or research support from, or having served as a consultant or adviser to, pharmaceutical companies, including Astellas, Cubist Pharmaceutical, Forest, Merck, Ortho-McNeil, Pfizer, Sanofi-Aventis, Schering-Plough, and Theravance. The remaining authors of the guidelines, including the lead author, Dr. Catherine Liu, reported no conflicts.

The Infectious Diseases Society of America rolled out its first-ever guidelines for treating methicillin-resistant Staphylococcus aureus – including recommendations to battle the growing threat posed by MRSA-related skin and soft-tissue infections.

The comprehensive guidelines also outline evidence-based approaches on topics ranging from personal hygiene and wound care to antibiotic therapies for invasive MRSA, as well as options after vancomycin treatment failure.

The guidelines' primary objective is "to provide recommendations on the management of some of the most common clinical syndromes encountered by adult and pediatric clinicians who care for patients with MRSA infections," according to the executive summary, published online Jan. 5 (Clin. Infect. Dis. 2010 [doi:10.1093/cid/ciq146]).

The guidelines provide adult and pediatric clinicians with guidance on how to treat relatively uncomplicated MRSA infections, as well as more serious infections, according to Dr. Catherine Liu, the guidelines' lead author and assistant clinical professor in the division of infectious diseases, University of California, San Francisco. The recommendations cover community- and hospital-associated MRSA infections, she added.

MRSA infections account for about 60% of skin infections seen in U.S. emergency departments, and invasive MRSA infections cause about 18,000 deaths a year, according to the Infectious Diseases Society of America (IDSA).

The evidence-based guidelines, which will be published in the Feb. 1 issue of Clinical Infectious Diseases, have been endorsed by the Pediatric Infectious Diseases Society, the American College of Emergency Physicians, and the American Academy of Pediatrics.

The guidelines are voluntary and "are not intended to take the place of a doctor's judgment, but rather support the decision-making process, which must be individualized according to each patient's circumstances," according to a statement issued by IDSA, which funded the guidelines.

A 13-member expert panel reviewed hundreds of scientific studies, papers, and presentations to create the recommendations. The guidelines' sections start with a clinical question, followed by a numbered list of recommendations and a summary of the most relevant evidence to support the recommendations. In most cases, the sections include information on pediatric considerations. The guidelines also highlight areas that are controversial because of limited or conflicting data.

The first topic addressed is the management of skin and soft tissue infections due to MRSA, which have become a significant problem in the past few years, Dr. Liu said in an interview. For example, MRSA is now the predominant organism causing skin infections in patients who present to emergency departments with skin infections, she noted.

The guidelines cover multiple types of skin infections, including abscesses, cellulitis, and more complicated skin infections. The guidelines also offer recommendations on the role of antibiotics, including whether or not they need to be used, situations in which they may not be indicated, and when they definitely should be used. They also offer guidance " on specific types of antibiotic choices that clinicians should consider," Dr. Liu noted.

Other topics covered include the management of MRSA pneumonia, bacteremia, and infective endocarditis; central nervous system infections; and bone and joint infections. Additional sections review the role of adjunctive therapies in the treatment of MRSA infections, MRSA infections in neonates, and specific recommendations on vancomycin dosing and monitoring.

IDSA will update the guidelines as more information and newer antibiotics become available. However, timely updating can be difficult because of the review and publication process, Dr. Liu noted.

For example, the Food and Drug Administration approved the intravenous cephalosporin antibiotic ceftaroline in October 2010 for acute bacterial skin and soft tissue infections, including cases caused by MRSA. But approval came after the IDSA guidelines were finalized, and that information was not included. Nonetheless, the guidelines note that ceftaroline "may become available in the near future for the treatment" of complicated skin and skin structure infections, Dr. Liu said.

The guidelines do not address active surveillance testing or other strategies aimed at preventing MRSA in health care settings, topics that have been addressed in previously released guidelines.

IDSA funded the development of the guidelines. Of the expert panel's 13 members, 9 reported having potential conflicts of interest that included honoraria or research support from, or having served as a consultant or adviser to, pharmaceutical companies, including Astellas, Cubist Pharmaceutical, Forest, Merck, Ortho-McNeil, Pfizer, Sanofi-Aventis, Schering-Plough, and Theravance. The remaining authors of the guidelines, including the lead author, Dr. Catherine Liu, reported no conflicts.